(Q42995346)

12 November 2017

title

Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus (English)

1 reference

12 November 2017

1 reference

hepatocellular carcinoma

1 reference

Chao-Hung Hung

1

1 reference

12 November 2017

Chuan-Mo Lee

2

1 reference

12 November 2017

Jing-Houng Wang

3

1 reference

12 November 2017

Hung-Da Tung

4

1 reference

12 November 2017

Chien-Hung Chen

5

1 reference

12 November 2017

Sheng-Nan Lu

6

1 reference

12 November 2017

publication date

1 October 2005

1 reference

Journal of Gastroenterology and Hepatology

12 November 2017

published in

1 reference

12 November 2017

volume

20

1 reference

12 November 2017

issue

10

1 reference

12 November 2017

page(s)

1553-1559

1 reference

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.03925.X

Long-term course of interferon-treated chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.03925.X

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.03925.X

Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.03925.X

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.03925.X

Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.03925.X

Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.03925.X

Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.03925.X

Ablative techniques for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.03925.X

Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.03925.X

Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.03925.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.03925.X

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.03925.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.03925.X

Classification of chronic hepatitis: diagnosis, grading and staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.03925.X

A simulation study of the number of events per variable in logistic regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.03925.X

Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.03925.X

Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.03925.X

Sustained biochemical remission after interferon treatment may closely be related to the end of treatment biochemical response and associated with a lower incidence of hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.03925.X

10.1111/J.1440-1746.2005.03925.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference